



**SUPPLEMENTARY FIG. S2.** GABA<sub>A</sub> receptor agonists, in combination with Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>-</sup> (NKCC1) co-transporter blockers, can reduce the median membrane potential across a wide range of pathological ion concentrations. **(A)** Effect of GABA<sub>A</sub> receptor agonists on the percent change in median membrane potential of the regular spiking (RS) neuron model for mild traumatic brain injury (TBI). Note that values >0 represent a pathological worsening reflecting depolarization of the median membrane potential, whereas values <0 represent therapeutic benefits caused by hyperpolarization of the median membrane potential. Under these conditions, GABA<sub>A</sub> receptor agonists lose their therapeutic efficacy as the intracellular chloride concentration exceeds the physiological range. **(B)** Same as in **A**, but for the combination of GABA<sub>A</sub> receptor agonist and NKCC1 co-transporter blocker. By blocking NKCC1 co-transporter and hence reducing intracellular chloride concentration, this combination of drugs can hyperpolarize the model neuron (and thus help to rescue it from depolarization block) across a wide range of intracellular chloride concentrations. This suggests that this combination of drugs can have a therapeutic benefit in post-TBI brain states. **(C, D)** Same as **A, B**, but for  $K_{\text{outside}} = 18.5 \text{ mM}$ , reflecting more severe TBI.